Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT in hospitalized adults with acute schizophrenia (EMERGENT-1)
NCT03697252Phase 2Completed
- Sponsor
- Karuna Therapeutics
- Start
- Sep 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Started Sep 2018; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03697252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697252.